Arthneeti
CL

Curis Lifesciences Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Curis Lifesciences Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Curis Lifesciences Ltd Q2 FY27 key numbers

Revenue
Other income increased to Rs. 45.56 lakh from Rs. 0.12 lakh year-on-year for the quarter.

As stated in Curis Lifesciences Ltd's Q2 FY27 results statement · published 11 Nov 2026. Reported figures, not investment advice.

Based on Curis Lifesciences Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹171
Market cap₹138 Cr
P/E19.9

The short version

Revenue from operations for the quarter ended 30.09.2026 (consolidated) was Rs. 3703.39 lakh, compared to Rs. 2790.89 lakh for the quarter ended 30.09.2025 (standalone), indicating a year-on-year incr. EBITDA for the quarter ended 30.09.2026: Rs. 567.03 lakh (Consolidated).

From Curis Lifesciences Ltd's Q2 FY27 earnings-call transcript · updated 11 Nov 2026.

How did Curis Lifesciences' revenue grow in the September 2026 quarter?

- Revenue from operations for the quarter ended 30.09.2026 (consolidated) was Rs. 3703.39 lakh, compared to Rs. 2790.89 lakh for the quarter ended 30.09.2025 (standalone), indicating a year-on-year increase of approximately 32.8%. - Other income increased to Rs. 45.56 lakh from Rs. 0.12 lakh year-on-year for the quarter. - Total income for the quarter rose to Rs. 3748.95 lakh from Rs. 2791.01 lakh for the same quarter last year. All figures are on a consolidated basis for 30.09.2026 and standalone basis for 30.09.2025, and comparative figures are not strictly comparable due to recent acquisitions.

What happened to Curis Lifesciences' margins in Q2 FY27?

See what Curis Lifesciences Ltd said on profitability & margins — free account, 30 seconds.

What capex is Curis Lifesciences planning?

The closest related information on page 13 under "Cash flow from investing activities" includes: - Capital expenditure on fixed assets including capital advances of Rs. 258.63 lakh for the half year ended 30 September 2026 (Rs. 180.19 lakh for the year ended 31 March 2026). - Capital work in progress valued at Rs. 346.73 lakh as at 30 September 2026 (up from Rs. 132.74 lakh as at 31 March 2026), indicating ongoing investments.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1Ind-Swift Laboratories
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Curis Lifesciences raising money or cutting debt?

See what Curis Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Curis Lifesciences' order book?

See what Curis Lifesciences Ltd said on order book & pipeline — free account, 30 seconds.

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Continue your research

What Curis Lifesciences's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bal Pharma (Q2 FY27)

    Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…

  • Bafna Pharmaceuticals (Q2 FY27)

    INR 3,546.82 Lakhs, approximately 34.4% increase. Key results statement takeaways from Bafna Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks

  • Quest Laboratories (Q2 FY27)

    Revenue from operations for the half year ended 30th September 2026 is ₹5,533.55 lakhs, compared to ₹4,880.48 lakhs for the half year ended 30th September…

  • Haleos Labs Limited (Q2 FY27)

    1,036.03 Lakhs (~13.3% growth). Key results statement takeaways from Haleos Labs Limited's Q2 FY27 results statement — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Curis Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Curis Lifesciences Ltd Q2 FY27 results?

Revenue from operations for the quarter ended 30.09.2026 (consolidated) was Rs. 3703.39 lakh, compared to Rs. 2790.89 lakh for the quarter ended 30.09.2025 (standalone), indicating a year-on-year incr. EBITDA for the quarter ended 30.09.2026: Rs. 567.03 lakh (Consolidated).

What is Curis Lifesciences Ltd share price analysis?

Curis Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 19.9 with a market cap of ₹138 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Curis Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.